Agilent agrees to buy digital pathology software provider Proscia for $240 million cash upfront

By Public Technologies
  • Agilent agreed to buy digital pathology software provider Proscia in an all-cash deal valued at USD 240 million at closing.
  • Deal includes up to USD 30 million in additional payments tied to future performance milestones.
  • Proscia serves more than 4,000 labs, hospitals, and clinics, with trailing 12-month revenue exceeding USD 18 million.
  • Transaction expected to close early in Agilent’s fiscal year 2027; Proscia will join its Life Sciences and Diagnostics Markets Group.
  • Acquisition expands Agilent’s digital pathology footprint, adding vendor-agnostic workflow software with FDA 510(k) clearance for primary diagnosis.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agilent Technologies Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261013873030) on October 13, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.